Invivyd, Inc. (NASDAQ:IVVD) Short Interest Update

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) saw a large drop in short interest in April. As of April 15th, there was short interest totalling 7,010,000 shares, a drop of 15.1% from the March 31st total of 8,260,000 shares. Approximately 9.2% of the shares of the company are short sold. Based on an average trading volume of 14,470,000 shares, the days-to-cover ratio is currently 0.5 days.

Invivyd Stock Performance

Invivyd stock traded down $0.03 during trading hours on Thursday, hitting $0.56. 1,200,383 shares of the stock were exchanged, compared to its average volume of 4,333,131. Invivyd has a 12 month low of $0.35 and a 12 month high of $2.74. The business's 50-day moving average is $0.66 and its two-hundred day moving average is $0.76. The stock has a market capitalization of $67.20 million, a P/E ratio of -0.29 and a beta of 0.40.

Invivyd (NASDAQ:IVVD - Get Free Report) last issued its earnings results on Thursday, March 20th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.10. The firm had revenue of $13.80 million during the quarter, compared to the consensus estimate of $13.57 million. On average, equities analysts predict that Invivyd will post -1.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Invivyd

Several hedge funds and other institutional investors have recently made changes to their positions in the company. XTX Topco Ltd bought a new position in shares of Invivyd during the first quarter worth about $66,000. Jane Street Group LLC boosted its holdings in shares of Invivyd by 290.5% in the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock worth $52,000 after buying an additional 87,358 shares during the last quarter. Barclays PLC grew its stake in shares of Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company's stock worth $120,000 after acquiring an additional 75,780 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Invivyd during the fourth quarter worth $74,000. Finally, JPMorgan Chase & Co. lifted its stake in Invivyd by 644.1% in the 4th quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company's stock worth $114,000 after purchasing an additional 222,375 shares in the last quarter. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently commented on IVVD. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Invivyd in a research report on Wednesday, March 26th. D. Boral Capital reaffirmed a "buy" rating and set a $9.00 price objective on shares of Invivyd in a research note on Thursday, March 20th.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.